CD39/CD73: the critical targets for adenosinergic pathways
The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment.
CD39 and CD73, two of the Ectonucleotidases, are involved in converting ATP into extracellular adenosine. CD39 (ectonucleoside triphosphate diphosphohydrolase-1, ENTPD1) converts ATP and ADP to AMP, and CD73 (ecto-5′-nucleotidase, NT5E) converts AMP to adenosine (ADO). ADO is a key metabolite within the TME that accumulates and inhibits the function of important immune cells, including T cells and NK cells, leading to an environment conducive to tumor growth. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer.
주문Assay Data
High purity verified by MALS
-
-
The purity of Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) was greater than 90% as determined by SEC-HPLC.
-
Request Report
High bioactivity
ELISA
Immobilized Human CD39, His Tag (Cat. No. CD9-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-CD39 Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).
Request Protocol
BLI
Loaded Anti-CD73 MAb (Human IgG1) on AHC Biosensor, can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.179 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Request Protocol
SPR
Anti-CD73 antibody (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Request Protocol
High enzymatic activity
| Product | Human CD39 / ENTPD1 Protein, His Tag | Human CD73 / NT5E Protein, His Tag (HPLC-verified) | ||
| Hydrolyzed substrate | Adenosine-5'-triphosphate (ATP) | Adenosine-5'-monophosphate (AMP) | ||
|
Enzymatic activity （pmol/min/μg） |
ACRO product （Cat. No: CD9-H52H4） |
The product of another vendor |
ACRO product （Cat. No: CD3-H52H7） |
The product of another vendor |
| > 6,000 | >5,000 | >37,000 | >15,000 | |
Note: The enzymatic activity of the same product is measured under the same conditions
FAQ
What are the key requirements for recombinant CD39 and CD73 proteins in therapeutic inhibitor screening?
Reliable inhibitor screening requires catalytically active enzymes with documented activity, purity, and consistency. ACROBiosystems offers recombinant CD39 and CD73 proteins with product-specific enzyme activity validation and analytical characterization. These reagents support biochemical inhibitor screening and the assessment of target-specific enzymatic inhibition.
What research tools are needed to evaluate combined CD39 and CD73 inhibition in the extracellular adenosine pathway?
Combined CD39/CD73 inhibition is being investigated to reduce extracellular adenosine production at consecutive enzymatic steps. Evaluating this approach requires evidence of inhibition at each target, alongside measurements of overall pathway activity. ACROBiosystems provides enzymatically active recombinant CD39 and CD73 proteins for individual inhibitor characterization, supporting biochemical studies that complement downstream pathway and cellular functional assays.
Why is native CD73 conformation important when selecting recombinant antigens for therapeutic antibody screening?
CD73 functions as a homodimer, and conformational transitions between open and closed states are involved in catalysis. Certain inhibitory antibodies recognize conformation-dependent epitopes or restrict these transitions. ACROBiosystems provides recombinant CD73 proteins with product-specific binding, activity, and analytical data, supporting antigen selection for antibody screening. Oligomeric-state evidence and functional activity should be considered together rather than treating purity alone as proof of native conformation.
What assay reagents are needed to characterize biparatopic antibodies targeting CD73?
Biparatopic CD73 antibodies can recognize distinct epitopes and restrict conformational changes required for catalysis. Their characterization may involve individual epitope binding, competition, and enzymatic inhibition. ACROBiosystems provides recombinant CD73 proteins in selected formats for binding and functional studies. These reagents can support assay development, while simultaneous epitope engagement and antibody-mediated crosslinking require additional experimental validation.
How should I choose among His-, Fc- and biotinylated Avi-tag formats?
Choose a His-tagged protein for common capture or purification workflows, an Fc-tagged protein when Fc-based immobilization is useful, and a biotinylated His/Avi format for streptavidin-based capture. Confirm the exact format in the product name.
What should be considered when assessing FcγR-mediated effects of therapeutic anti-CD39 or anti-CD73 antibodies?
Some CD39/CD73-targeting antibodies are investigated for mechanisms beyond catalytic inhibition, including Fc-dependent immune effector functions. Assessing these activities requires distinguishing target recognition from FcγR engagement. ACROBiosystems offers recombinant CD39/CD73 proteins and FcγR research reagents to support separate characterization of antigen binding and Fc–receptor interactions. Functional consequences such as ADCC or ADCP require appropriate cell-based evaluation.
- Background
- Product Features
- Product List
- Assay Data
- FAQ